Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

PSA doubling time of prostate carcinoma managed with watchful observation alone.

Choo R, DeBoer G, Klotz L, Danjoux C, Morton GC, Rakovitch E, Fleshner N, Bunting P, Kapusta L, Hruby G.

Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):615-20.

PMID:
11395227
2.
3.

The role of serial free/total prostate-specific antigen ratios in a watchful observation protocol for men with localized prostate cancer.

Do V, Choo R, De Boer G, Klotz L, Danjoux C, Morton G, Szumacher E, Fleshner N, Bunting P.

BJU Int. 2002 May;89(7):703-9.

4.
6.

Early outcomes of active surveillance for localized prostate cancer.

Hardie C, Parker C, Norman A, Eeles R, Horwich A, Huddart R, Dearnaley D.

BJU Int. 2005 May;95(7):956-60.

7.

Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.

Kollmeier MA, Stock RG, Stone N.

Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):645-53.

PMID:
14529768
8.

Evaluation of changes in prostate specific antigen in clinically localized prostate cancer managed without initial therapy.

Gerber GS, Gornik HL, Goldfischer ER, Chodak GW, Rukstalis DB.

J Urol. 1998 Apr;159(4):1243-6.

PMID:
9507845
9.

Observations of prostate specific antigen doubling time in Japanese patients with nonmetastatic prostate carcinoma.

Egawa S, Matsumoto K, Suyama K, Iwamura M, Kuwao S, Baba S.

Cancer. 1999 Aug 1;86(3):463-9.

PMID:
10430254
10.
11.
12.

Prostate-specific antigen spikes after permanent prostate brachytherapy.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Anderson RL.

Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):450-6.

PMID:
12243821
13.

[A clinical analysis of patients with early-stage prostate cancer managed without initial treatment].

Kawa G, Hiura Y, Satoh H, Sugi M, Fujita I, Oguchi N, Doi H, Ashida M, Okada H, Muguruma K, Murota T, Koyama Y, Kawamura H, Ohara T, Kawakita M, Matsuda T.

Hinyokika Kiyo. 2002 Mar;48(3):133-8. Japanese.

15.

Prostate-specific antigen velocity in untreated, localized prostate cancer.

Venkitaraman R, Norman A, Woode-Amissah R, Dearnaley D, Horwich A, Huddart R, Parker C.

BJU Int. 2008 Jan;101(2):161-4. Epub 2007 Sep 10.

16.

Comparison of histologic grade between initial and follow-up biopsy in untreated, low to intermediate grade, localized prostate cancer.

Choo R, Do V, Sugar L, Klotz L, Bahk E, Hong E, Danjoux C, Morton G, DeBoer G.

Can J Urol. 2004 Feb;11(1):2118-24.

PMID:
15003150
17.

Relationship between prostate volume, prostate-specific antigen nadir, and biochemical control.

Kaminski JM, Hanlon AL, Horwitz EM, Pinover WH, Mitra RK, Hanks GE.

Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):888-92.

PMID:
11958880
18.
19.

Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era.

Carter CA, Donahue T, Sun L, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Jackmaan S, Moul JW.

J Clin Oncol. 2003 Nov 1;21(21):4001-8.

PMID:
14581423
20.

Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer.

Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A.

J Clin Oncol. 2010 Jan 1;28(1):126-31. doi: 10.1200/JCO.2009.24.2180. Epub 2009 Nov 16.

PMID:
19917860

Supplemental Content

Support Center